桂林三金：公司创新药平台主要为旗下孙公司宝船生物，宝船生物聚焦肿瘤和自身免疫性疾病等治疗领域

Core Viewpoint - The company, Guilin Sanjin, confirmed that its innovative drug platform does not currently utilize CAR-T technology, focusing instead on developing biological drugs for cancer and autoimmune diseases through its subsidiary, Baoshuan Biotech [2]. Group 1: Company Overview - Guilin Sanjin's innovative drug platform is primarily operated by its subsidiary, Baoshuan Biotech [2]. - Baoshuan Biotech is dedicated to the treatment of tumors and autoimmune diseases, emphasizing the development and screening of biological drugs targeting various cancers and autoimmune conditions [2]. Group 2: Technology Focus - The company has stated that it does not have any innovative drugs that incorporate CAR-T technology at this time [2].